Exemestane 25 mg

Exemestane 25 mg contains the steroidal aromatase inhibitor exemestane. In clinical medicine, it is approved for treatment of hormone receptor-positive breast cancer in postmenopausal women . In non-medical bodybuilding contexts, it is commonly referenced for managing estrogenic side effects from aromatizing anabolic steroids, though such use falls outside approved indications.

The standard clinical dose is 25 mg taken once daily after a meal for breast cancer treatment . In non-medical contexts, exemestane is commonly referenced at lower doses of 6.25–25 mg daily or every other day. These non-medical practices are not derived from controlled clinical trials for performance enhancement.

Exemestane is an aromatase inhibitor, not an anabolic steroid, and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to exemestane in the context of hormonal recovery. In non-medical settings, PCT protocols typically involve Clomiphene or Tamoxifen rather than exemestane.

Exemestane is a steroidal aromatase inhibitor that irreversibly binds to the aromatase enzyme (CYP19A1), permanently disabling its ability to convert androgens into estrogens . This mechanism produces sustained estrogen suppression until new enzyme is synthesized. It is distinct from non-steroidal AIs such as anastrozole, which bind reversibly.

Exemestane has a terminal elimination half-life of approximately 24 hours, and steady-state plasma concentrations are typically reached within 7 days of daily administration . Estrogen suppression begins rapidly after the first dose, though the irreversible mechanism means effects persist even after the drug is cleared from circulation .

There is no universally established "best" aromatase inhibitor, and each has distinct characteristics. Exemestane is a steroidal AI with an irreversible mechanism, while anastrozole and letrozole are non-steroidal AIs with reversible binding . In the TEAM trial, exemestane demonstrated efficacy comparable to tamoxifen with a different side effect profile .

Exemestane and Anastrozole are both aromatase inhibitors but differ in type. Exemestane is a steroidal, irreversible (suicide) inhibitor, while anastrozole is a non-steroidal, reversible inhibitor. Exemestane's effects persist until new enzyme is synthesized, and it does not negatively affect LH/FSH feedback at moderate doses .

Exemestane and Letrobol (letrozole) are both aromatase inhibitors. Exemestane is steroidal with an irreversible mechanism, while letrozole is non-steroidal with reversible binding. Letrozole is generally considered more potent at suppressing estrogen, while exemestane's steroidal structure may offer different side effect characteristics.

Exemestane 25 mg is the standard clinical dose for breast cancer treatment in postmenopausal women . In non-medical bodybuilding contexts, 25 mg is often considered a high dose for estrogen management, and lower doses or less frequent administration are commonly referenced to avoid excessive estrogen suppression.

Exemestane 25 mg is labeled at 25 mg of exemestane per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.

Yes. A published laboratory report dated March 23, 2026 measured Exemestane 25 mg at 23.64 mg, equivalent to 94.56% of its 25 mg label claim. The complete report can be viewed in the Lab Reports tab.